IrelandIreland

Fragmented alliance in cancer drugs

07.12.2011

Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery, a member of the Almac Group, located in Craigavon, Northern Ireland. "We have been impressed with Beactica’s expertise and capabilities in SPR biosensor-based drug discovery and are looking forward to a fruitful collaboration on these important targets", said Tim Harrison, VP Medicinal Chemistry at Almac Discovery. "We plan to take projects to clinical proof of concept (or earlier) before out-licensing or partnering for further development”. Beactica specialises in surface plasmon resonance (SPR) biosensor- based small molecule interaction analysis and offers partnerships for fragment-based lead generation using its Sprint platform. Founded in 2006 based on research carried out at Uppsala University, Beactica is regarded as a leader in SPR biosensor-based small molecule drug discovery.

IrelandIreland

14.10.2009

Dublin – Amarin Corporation plc today announced it has entered into an agreement with a number of investors for a $70 million private placement. The placement of units for $70 million consists of $66.4 million in cash proceeds...

IrelandIreland

19.09.2009

Dublin – The Republic of Ireland has amended its patent law to bring it into line with the rest of Europe and make its domestic patenting system more straightforward. The government said increased levels of research in Ireland in...

IrelandIreland

10.08.2009

Dublin - The honeymoon between Elan and Biogen has been over for a long time, now the marriage of the Irish biotech company and their US partner lies in ruins. The Elan Corporation has filed suit against Biogen Idec Inc. In the...

IrelandIreland

12.07.2009

Dublin – Ireland is focussing on expanding productivity in the upstream processing of biological drugs. Science Minister Conor Lenihan has announced EUR2.3m in funding for the next 3 years aimed at delivering more efficient and...

IrelandIreland

07.07.2009

Dublin/New Brunswick – Pharma giant Johnson &Johnson will buy all assets of Irish Elan Pharmaceuticals’ Alzheimer’s Immunotherapy Programme (AIP) through a newly formed company. The new company will pay $1 billion for an 18.4%...

IrelandIreland

17.06.2009

Dublin – Trinity College of Dublin's Institute of Molecular Medicine has opened Ireland´s first next generation DNA sequencing facility. The platform, built upon the current market-leading “Illumina Genome Analyzer II“ platform,...

IrelandIreland

14.06.2009

Dublin – Trinity College Dublin spin-out Opsona Therapeutics, a specialist in autoimmune and inflammatory diseases, has announced that the Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3m to the...

IrelandIreland

22.04.2009

Dublin – Ireland fears growing rates of resistant pneumococcus in the country's hospitals. A recent report by the Health Protection Surveillance Centre (HSPC) shows that 32% of 124 clinical isolates tested were non-susceptible to...

IrelandIreland

31.10.2008

Cork – Ireland is set to lose another 180 pharma jobs after pharmaceutical giant Pfizer announced it had failed to find a buyer for one of its five manufacturing facilities in the country. For the past 18 months, the company has...

IrelandIreland

14.08.2008

Dublin/Zurich – Analyst Ian Hunter of Goodbody Stockbrokers has maintained his “add” rating on Irish Elan Corp Plc. The fair value for the pharma combine has been raised from EUR18 to EUR19. The analyst says that the company has...

Displaying results 21 to 30 out of 49

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-ireland/browse/2/article/fragmented-alliance-in-cancer-drugs.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SUMMIT (UK)4.03 GBP3.87%
  • DEINOVE (F)13.32 EUR2.46%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 12.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events